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The global obesity epidemic has resulted in significant 
morbidity and mortality. However, the medical treatment 
of obesity is limited. Gastric bypass is an effective surgical 
treatment but carries signifi cant perioperative risks. The gut 
hormones, peptide tyrosine tyrosine (PYY) and glucagon-like 
peptide 1 (GLP-1), are elevated following gastric bypass and 
have been shown to reduce food intake. They may provide 
new therapeutic targets. This review article provides an over-
view of the central control of food intake and the role of PYY 
and GLP-1 in appetite control. Key translational animal and 
human studies are reviewed. (Gut Liver 2012;6:10-20)
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INTRODUCTION
It is currently estimated that nearly 2 billion adults worldwide 
are overweight (defined by a body mass index [BMI] ≥25 kg/
m2) and a further estimated 500 million are obese (BMI ≥30 kg/
m2). In 2008, The Health Survey of England classified 24% of 
adults and 16% of children as obese. These figures are rising 
sharply due to readily available high-calorie food and sedentary 
lifestyle. On a national level, extrapolations reveal that 40% 
of adults could be obese by 2025. It is well known that being 
overweight or obese carries an increased risk of type 2 diabetes, 
vascular disease, osteoarthritis, sleep apnoea and malignancy. 
It has even been predicted that the coming decades could see 
a reversal of twentieth century gains in life expectancy, due to 
detrimental health consequences arising from the obesity epi-
demic.1
Effective treatment of obesity has been shown worthwhile; 
a 92% reduction in diabetes deaths, 60% reduction in cancer 
deaths, 56% reduction in coronary artery disease deaths and 
40% reduction in all-cause mortality was demonstrated in a 
Correspondence to: Stephen R. Bloom
Department of Diabetes, Endocrinology and Metabolism, Hammersmith Campus, Imperial College London, Du Cane Road, London W12 0NN, UK
Tel: +44-0208-383-3242, Fax: +44-0208-383-8320, E-mail: s.bloom@imperial.ac.uk
Received on June 21, 2011. Accepted on July 19, 2011.
pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.1.10
 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
retrospective matched cohort study of obese individuals under-
going bariatric surgery.2 Bariatric surgery, in particular Roux-
en-Y gastric bypass (which involves the formation of a small 
stomach pouch and bypass of the proximal small bowel), is the 
most effective current treatment for obesity, leading to sustained 
weight loss of approximately 30%.3 However, the procedure is 
not without risk and carries a mortality rate of 0.5%.4
Lifestyle modification strategies (diet and exercise) currently 
form the main treatments for obesity. However, results are gen-
erally disappointing and the majority of people who attempt 
lifestyle modification regain any lost weight within 5 years.5 
Drug treatments sibutramine and rimonabant were recently 
withdrawn due to cardiovascular and neuropsychiatric side ef-
fects respectively. The only licensed pharmacological treatment 
for obesity in the UK is orlistat, an intestinal lipase inhibitor. 
This produces modest weight loss (in a systematic review of 
randomized clinical trials, 60% of patients on orlistat achieved 
>5% weight loss after 1 year of treatment).6 Furthermore, as a 
consequence of its mechanism of action, orlistat often leads to 
unacceptable gastrointestinal side effects when fat is consumed. 
In 2010, the U.S. Food and Drug Administration (FDA) commit-
tee recommended approval for Contrave (Orexin Therapeutics 
Inc. and Takeda Pharmaceutical Co.) for the treatment of obe-
sity. Contrave is a combination of naltrexone and bupropion, 
which act on central pathways to inhibit appetite. A multicen-
tre, randomised, double-blind, placebo-controlled phase 3 trial 
of Contrave had demonstrated that just under half of patients 
achieved >5% weight loss after 1 year of treatment.7 However, 
despite the professional committee recommendation, lack of 
data made it difficult to assess the safety of Contrave in patients 
at risk for heart disease and stroke, so the FDA has not licensed 
the agent without further trial. Thus cardiovascular side effects 
remains a concern, given that such conditions are themselves 
inherently linked to obesity. 
Accumulation of excess body fat (and hence development of 
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obesity) occurs when energy intake exceeds energy expenditure 
in the long term. The intricacies underpinning this fine-tuned 
regulation of energy balance form part of a complex field that 
has been the focus of intense research over the past decade, 
bridging the disciplines of endocrinology, gastroenterology and 
neurobiology. Our progressive understanding of the physiologi-
cal mechanisms of appetite regulation should help with the 
development of future pharmacological approaches to combat 
obesity. In particular, identification of how hormones that are 
secreted post-prandially by the gut interact with brain regions 
that modulate appetite may eventually allow for their manipu-
lation as therapeutic strategies in obese patients. These anorectic 
gut hormones, amongst others, include peptide tyrosine-tyrosine 
(PYY) and glucagon-like peptide 1 (GLP-1). Although these pep-
tide hormones will form the focus of this review article, in order 
to appreciate their roles in the control of appetite (and thus 
potential for development as anti-obesity agents), a brief prior 
overview of the neural control of feeding is necessary.
CO-ORDINATION OF APPETITE
Post-prandially, activation of gut mechanoreceptors, changes 
in circulating nutrient concentration, and release of anorectic 
gut hormones all lead to a reduction in subsequent feeding.8 
Longer term adiposity signals of energy balance such as leptin 
also interact with central nervous system (CNS) circuits to regu-
late food intake.9,10 However, apart from traditional homeostatic 
feedback regulation of energy balance, a variety of other factors 
influence food intake. These include food appearance, flavour 
and availability in addition to social, cultural, and economic 
influences. Importantly, there is also modulation of food intake 
by hedonic and mnemonic neuronal circuits.11 The modern con-
sensus is therefore that there is interaction between homeostatic 
and non-homeostatic inputs, which together lead to co-ordi-
nation in terms of inducing either an orexigenic or anorectic 
response. Fig. 1 summarises the major determinants of appetite 
control. 
THE HYPOTHALAMUS
The hypothalamus, in particular the arcuate nucleus (ARC) 
within it, is thought to be pivotal in appetite regulation. By vir-
tue of lying close to the median eminence (a circumventricular 
organ where an incomplete blood-brain barrier is thought to 
allow peripheral signals to gain access to the CNS), the ARC is 
ideally positioned to co-ordinate feeding. Lesions of the ARC 
result in hyperphagia and obesity in mice.12
Within the ARC, one discrete group of neurons contains neu-
ropeptide Y (NPY) and agouti-related peptide (AgRP), activa-
tion of which enhances food intake.13 Another group comprises 
anorexigenic neurons containing pro-opiomelanocortin (POMC) 
and cocaine- and amphetamine-regulated transcript (CART). 
POMC is the precursor of α-melanocyte stimulating hormone 
(α-MSH), which acts on melanocortin receptors (mainly MC4R) 
to reduce food intake.14 Furthermore, AgRP is a competitive 
antagonist at melanocortin receptors.15 CART is thought to have 
either orexigenic or anorexigenic effects depending on its site of 
action; central intracerebroventricular administration of CART 
reduces food intake in rats,16 whereas administration of CART 
directly into the ARC increases food intake.17
Axons from NPY/AgRP and POMC/CART neurons project 
from the ARC to other hypothalamic nuclei; one important ex-
ample being the paraventricular nucleus (PVN). Destruction of 
the PVN leads to hyperphagia and obesity in rats.18
THE BRAINSTEM
The brainstem dorsal vagal complex (DVC) comprises the 
nucleus of the tractus solitarius (NTS), the area postrema (AP), 
and the dorsal motor nucleus of the vagus. The DVC is thought 
to be an important communication link between peripheral 
signals of food intake and hypothalamic nuclei.19 The absence 
of a complete blood-brain barrier in the AP may facilitate this. 
It is well established that there are neural projections from the 
brainstem to the hypothalamus20 and vice-versa.21 Additionally, 
vagal nerve afferents carry sensory information from the gut 
directly to the NTS. In support of this, transection of these gut 
sensory vagal nerve afferents results in increased meal size and 
duration.22
REWARD (HEDONIC) AND MNEMONIC PATHWAYS
Cortico-limbic ‘reward centres’ implicated in appetite regula-
tion include the hippocampus, amygdala, nucleus accumbens, 
dorsal and ventral striatum, insula, anterior cingulate and pre-
frontal cortex. Communication between these regions and the 
brainstem or hypothalamus culminates in overall co-ordination 
of food consumption. In support of this, orexin neuron expres-
sion in the hypothalamus is increased by administration of an 
opioid μ-receptor agonist into the nucleus accumbens.23 Fur-Fig. 1. The major determinants of appetite control.
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thermore, in rats trained to associate the presentation of a food 
cup with the availability of food (resulting in conditioned food 
intake even in situations where they are satiated), the condition-
ing is abolished by disruption of amygdala-hypothalamus con-
nections.24
With respect to linking reward to hedonic experience, recent 
evidence points to an important role for the orbitofrontal cortex 
(OFC), an area that receives converging sensory input.25 The 
OFC is in contact with other cortical reward areas, such as the 
prefrontal, insular, and anterior cingulate cortices. Furthermore, 
there is communication between the OFC, hippocampus and 
amygdala. The network of communication between these brain 
regions is thought to play a role in the formation and mainte-
nance of a working memory for food experiences.26
THE ROLE OF GUT HORMONES IN THE CONTROL OF AP-
PETITE
The gut is the largest endocrine organ in the body and se-
cretes over 30 different regulatory peptide hormones. A number 
of these gut hormones are stimulated by gut nutrient content 
and interact with receptors at various points in the ‘gut-brain 
axis’ to affect short term and intermediate term feelings of hun-
ger and satiety. The major gut hormones implicated in appetite 
control are outlined in Table 1. This review will focus on the 
role of the anorectic gut hormones PYY and GLP-1. Both hor-
mones are released together following a meal to mediate post-
prandial satiety. As discussed previously, gastric bypass surgery 
is one of the most effective treatments for obese patients, where 
sustained weight loss results from diminished appetite. Notably, 
gastric bypass patients demonstrate increased levels of PYY and 
GLP-1, especially post-prandially.27-29 Significantly, inhibiting 
the PYY and GLP-1 responses results in return of appetite and 
increases food intake.29 Therefore, it is likely that elevated lev-
els of PYY and GLP-1 play a key role in the sustained weight 
loss observed following gastric bypass surgery. It follows that 
investigation into the physiological interaction between these 
hormones and the CNS is of paramount importance in obesity 
research. 
PYY
PYY is a 36-amino acid peptide which belongs to the pancre-
atic polypeptide (PP) family. This family of peptides, comprising 
PP, PYY, and NPY, share a common hair-pin-fold motif struc-
ture. PP, PYY, and NPY bind to G-protein coupled receptors Y1, 
Y2, Y4, Y5, and Y6, displaying promiscuity in their interactions 
with these receptors by virtue of their shared hair-pin-fold motif 
structure.
PYY is produced by the L cells of the gut, with highest con-
centrations found in the large bowel and the rectum.30 Two en-
dogenous forms, PYY1-36 and PYY3-36, are released post-prandi-
ally into the circulation. PYY3-36 is further produced by cleavage 
of the Tyr-Pro amino terminal residues of PYY1-36 by the enzyme 
dipeptidyl peptidase IV (DPP-IV). PYY3-36 acts mainly via the 
Y2 receptor.
31 Indeed, PYY3-36 selectivity for the Y2 receptor is 
thought to be conferred by cleavage of the Tyr-Pro amino termi-
nal residues of PYY1-36.
31 In the fasted state, PYY1-36 predominates 
in the circulation, whereas post-prandially, PYY3-36 is the major 
circulating form.32 Following a meal, circulating levels of PYY3-36 
Table 1. The Major Gut Hormones Involved in Appetite Regulation
Hormone Site of secretion Major receptors Major actions
Anorectic PYY Gastrointestinal L cells Y2 Delays gastric emptying
Vagal and CNS effects
GLP-1 Gastrointestinal L cells GLP-1 Glucose dependant insulin release
Delays gastric emptying
Vagal and CNS effects
Oxyntomodulin Gastrointestinal L cells GLP-1/? other Glucose dependant insulin release
Delays gastric emptying
Vagal and CNS effects
Glucagon Pancreatic α cells Glucagon Gluconeogenesis
Glycogenolysis
Cholecystokinin Intestinal I cells CCK 2 Gall bladder contraction  
Delays gastric emptying 
Pancreatic enzyme secretion
Pancreatic polypeptide Pancreatic PP cells Y4 Delays gastric emptying
Amylin Pancreatic β cells AMY1-3 Inhibits gastric secretion
Delays gastric emptying
Decreases blood glucose
Orexigenic Ghrelin Gastric fundal A cells GHS-R Increases gastric motility 
Growth hormone release
PYY, peptide tyrosine tyrosine; CNS, central nervous system; GLP-1, glucagon-like peptide 1.
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rise within 15 minutes, peak at approximately 90 minutes and 
remain elevated for up to 6 hours.30 The magnitude of the rise 
in PYY3-36 is in proportion to the calories ingested.
33 When ex-
ogenously administered intravenously, its circulating half-life is 
approximately 8 minutes.34
Given that PYY3-36 is released within 15 minutes of food in-
take, this must occur before ingested nutrients reach the distal 
small intestine and colon (where the greatest concentrations 
of PYY3-36 are found). Therefore, initial post-prandial release 
of PYY3-36 is likely to be under neural control. Further release 
of PYY3-36 is observed when the nutrients arrive in the distal 
gut and is particularly stimulated by a high fat diet.35 The protein 
content of the diet is thought to be influential for delayed PYY3-36 
release approximately 2 hours post-prandially.36 PYY3-36 is likely 
to affect appetite via a direct central effect and also via its ef-
fects on gut motility - it acts as an ‘ileal brake’ and so leads to a 
sensation of fullness and satiety.37,38
Studies by Batterham et al.37,38 have shown that peripheral ad-
ministration of PYY3-36 to rodents and humans leads to marked 
inhibition of food intake. In humans, ad libitum food intake at a 
buffet meal served 2 hours after the completion of a 90 minute 
intravenous infusion of PYY3-36 delivered at a dose of 0.8 pmol/
kg/min, was reduced by 36% compared with an infusion of 
saline. The PYY3-36 infusion generated plasma levels of PYY3-36 
similar to those achieved physiologically after a meal.37 Thus, it 
was suggested that PYY3-36 inhibits food intake physiologically. 
Energy intake measured over the subsequent 24 hours after the 
infusion of PYY3-36 was reduced by 33% compared with saline. 
This pointed towards a role for PYY3-36 in the intermediate con-
trol of food intake beyond the study test meal. Significantly, 
there was no reported nausea in subjects infused with PYY3-36. 
Some studies have reported that obese individuals have lower 
basal fasting levels of PYY3-36 and have a smaller rise in post-
prandial levels.38 Obesity does not appear to be associated with 
resistance to PYY3-36, as in obese subjects, there was a 30% in 
a reduction in ad libitum food intake at a buffet meal served 2 
hours after completion of a 90 minute infusion of PYY3-36 deliv-
ered at an unspecified dose based on body surface area.38 This 
compared with a 31% reduction in food intake in a group of 
lean subjects who also received a peripheral infusion of PYY3-36. 
Additionally, there was also a comparable reduction in 24-hour 
energy intake in both lean and obese subjects following PYY3-36 
infusion. 
A similar study administered a 90 minute intravenous infu-
sion of PYY3-36 to lean and overweight human subjects at a dose 
of 0.8 pmol/kg/min, with 19% reduction in ad libitum food 
intake at a buffet meal served 2 hours after completion of the 
infusion.39 However, in contrast to the studies by Batterham et 
al., significant nausea was experienced by subjects, culminat-
ing in only 4 of the first 9 being able to complete their infusion. 
This study also found that there was increased thermogenesis, 
lipolysis, post-prandial insulin and glucose responses in those 
receiving PYY3-36, suggestive of increased sympathoadrenal ac-
tivity and increased energy expenditure. However, the effect of 
nausea on these latter findings is a potential confounder. 
Batterham et al.37 performed a series of experiments in rodents 
which shed considerable light on the action of PYY3-36 on CNS 
appetite circuits. Firstly, it was shown that chronic peripheral 
administration of PYY3-36 resulted in a decrease in food intake 
and body weight. Furthermore, a single peripheral injection of 
PYY3-36 resulted in induction of expression of the immediate-
early gene c-fos (a marker of neuronal activation) in the hypo-
thalamic ARC. This suggests that the ARC is an important site of 
action of the peptide. Furthermore, a single peripheral injection 
of PYY3-36 caused a decrease in expression of hypothalamic NPY 
mRNA 6 hours later. A subsequent single injection of PYY3-36 
directly into the ARC inhibited food intake. Inhibition of food 
intake was also observed with intra-arcuate administration of a 
Y2 receptor specific agonist. Significantly, this effect was absent 
in Y2 receptor knock-out mice. Addition of PYY3-36 to ex vivo 
hypothalamic explants inhibited release of NPY and stimulated 
release of α-MSH. This finding was further validated by electro-
physiological studies, which demonstrated that POMC neurons 
showed disinhibition when exposed to PYY3-36. It therefore 
appears that circulating PYY3-36 inhibits appetite by acting di-
rectly on the ARC via the Y2 receptor, increasing the activity of 
anorexigenic POMC/α-MSH neurons, whilst suppressing orexi-
genic NPY neurons. 
The Y2 receptor is abundantly distributed within the hypo-
thalamic ARC, preoptic nucleus and dorsomedial nucleus.40 
Given the presence of an incomplete blood-brain-barrier in the 
hypothalamic median eminence, which lies close to the ARC, 
it is plausible that circulating PYY3-36 accesses the CNS at this 
level. Furthermore, the Y2 receptor is found in the NTS of the 
brainstem.40 In keeping with this, peripheral injection of PYY3-36 
activates c-fos expression in the AP and the NTS.41 Therefore, 
circulating PYY3-36 may access the brainstem via the incomplete 
blood brain barrier at the AP. Taking into account the presence 
of ascending and descending projections between the brainstem 
and hypothalamus (as discussed earlier), it is possible that there 
is communication between these areas with regard to PYY3-36 
action. 
Other forebrain areas that express the Y2 receptor include the 
posterior hypothalamic nuclei, medial nucleus of the amygdala, 
substantia nigra, and parabrachial area.42 Action on the limbic 
system (including the amygdala) may be of significance when 
considering modulation of hedonic pathways by PYY3-36. 
PYY3-36 may also act via the vagus-brainstem-hypothalamic 
pathway, as evidenced by a series of experiments by Koda et 
al.43 This group showed using vagal ligation studies that Y2 
receptors are transported to the peripheral terminals of vagal 
afferent neurons. Furthermore, peripheral administration of 
PYY3-36 led to afferent vagal discharges, while disruption of the 
vagus-brainstem-hypothalamus pathway abolished its anorexi-
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genic effect. A summary of the interactions of PYY with the 
brainstem, hypothalamus and higher brain centres is shown in 
Fig. 2. 
Batterham et al.44 demonstrated that intravenous infusion of 
PYY3-36 to humans not only resulted in reduced food intake, but 
modulated activity in the hypothalamus and OFC, as assessed 
by functional magnetic resonance imaging. During saline infu-
sion visits, subjects’ caloric intake correlated with signal change 
in the hypothalamus, whereas this switched to the OFC on study 
visits when PYY3-36 was infused. It was postulated that the pres-
ence of PYY3-36 switches regulation of food intake from a ho-
meostatic brain region (hypothalamus) to a hedonic region (OFC). 
DEVELOPING PYY BASED TREATMENTS FOR OBESITY
The translational research on PYY3-36 thus far leads to the 
prospect that analogues of the peptide, delivered subcutane-
ously, may be used to treat obesity. This work is already under-
way, focussing on making changes to the peptide sequence to 
confer greater Y2 receptor selectivity and prolonged action in 
vivo. Conferring Y2 receptor selectivity is especially important, 
given that in contrast to peripheral and intra-ARC injection, 
administration of PYY3-36 into the 3rd ventricle or the PVN is 
orexigenic in mice.45,46 This is thought to be due to action on Y1 
and Y5 receptors in these regions. In contrast to the anorectic 
effect produced by Y2 receptor activation, Y1 and Y5 receptor 
activation promotes feeding.47
During future drug development, monitoring the effect of 
PYY analogues in reducing food intake without inducing nau-
sea will be a priority. Administration of intra-nasal PYY3-36 was 
tested in obese human subjects as a weight-loss treatment, but 
encountered significant problems with nausea and vomiting.48 
In this study, placebo or intra-nasal PYY3-36 was administered at 
a dose of 200 mcg 3 times daily or 600 mcg 3 times daily for 12 
weeks. Only 70% of subjects in the low-dose group completed 
the study and this figure was even lower (26%) in the high-
dose group. The mean weight loss from baseline over the 12 
weeks was 2.8 kg in the placebo group, 3.7 kg in the 200 mcg 
PYY3-36 group, and only 1.4 kg in the 600 mcg PYY3-36 group.
48 
Pharmacokinetics revealed rapid (Cmax 20 min) absorption of PYY3-
36 to pharmacological plasma levels. This is likely to have been a 
major contributor to nausea. 
Oral delivery of peptide hormones has been unsuccessful on 
the whole, due to the harsh environment of the gastrointestinal 
tract and thus failure of absorption across the intestinal wall. 
The subcutaneous route is therefore the established route for 
peptide hormone delivery; insulin being the classical example. 
However, it could be argued that oral administration of gut 
hormones better mimics the physiological post-prandial state 
(given that these peptides are naturally secreted from the gut, 
where they may act on local vagal afferents, in addition to be-
ing absorbed into the portal circulation before acting systemi-
cally). Subcutaneous administration does not allow for these 
potentially important local physiological gastrointestinal effects. 
Encouragingly, a recent study of oral delivery of PYY3-36 with 
sodium N-caprylate (Emisphere Technologies, Cedar Knolls, 
NJ, USA) to 12 healthy human subjects showed that there was 
effective absorption of the peptide from the gut.49 Supraphysi-
ological plasma levels were achieved, but despite this, no nau-
sea was encountered with administration of oral PYY3-36 alone. 
Energy intake at a buffet meal served 15 minutes later was 
reduced by 12% compared with placebo, although this was not 
found to be statistically significant. 24-hour energy intake was 
unchanged by oral PYY3-36 administration. The results are nev-
ertheless promising for the future oral administration of PYY3-36 
(and other gut hormones) as treatments for obesity. Emisphere’s 
Fig. 2. The role of PYY and GLP-1 
in appetite control. 
PYY, peptide tyrosine tyrosine; GLP-
1, glucagon-like peptide 1; ARC, ar-
cuate nucleus; NPY, neuropeptide Y; 
AgRP, agouti-related peptide; POMC, 
pro-opiomelanocortin; CART, co-
caine- and amphetamine-regulated 
transcript; ME, median eminence; 
AP, area postrema; NTS, nucleus of 
the tractus solitaries.
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sodium N-caprylate technology uses hydrophobic moieties on 
carrier molecules, which when in association with a peptide 
such as PYY3-36, allows for the creation of a more lipophilic 
complex. This facilitates absorption of the peptide across the 
intestinal wall. 
A summary of important translational human studies investi-
gating the role of PYY3-36 in appetite control and as a potential 
treatment for obesity is shown in Table 2. 
GLP-1
Proglucagon is a 160-amino acid prohormone that is pro-
duced in the α-cells of the pancreatic islets, the L cells of the 
distal gut and within the CNS. Selective post-translational 
proteolysis of proglucagon by prohormone convertases 1 and 
2 results in the tissue-specific production of a number of bio-
logically-active fragments. In the gut and CNS, with respect to 
the regulation of appetite and food intake, the cleavage product 
GLP-1 will be the focus of this section.
GLP-1 is released post-prandially into the circulation from 
the gastrointestinal L cells in proportion to the calories ingest-
ed.50,51 It has been shown that GLP-1 shows a biphasic response 
after a meal. As with PYY, the first peak occurs before nutrients 
enter the distal gut8 and has been shown to be augmented by a 
high-carbohydrate meal.52 This is presumably via the effect of 
carbohydrates absorbed in the proximal gut. It is thought that 
the second peak of secretion of GLP-1 is triggered by free fatty 
acids in the intestinal lumen, via activation of the G-protein 
coupled receptors GPR 40,53 GPR 119,54,55 and GPR 120.56 The 
two forms synthesized are GLP-11-37 and GLP-11-36 amide. Further 
cleavage produces the bioactive fragments GLP-17-37 and GLP-
17-36 amide. The major circulating bioactive species of GLP-1 is 
the truncated form GLP-17-36 amide.
51 It is rapidly broken down by 
DPP-IV and has a half-life of 2 minutes.57
GLP-1 acts by binding to the G-protein coupled GLP-1 recep-
tor (GLP-1R). GLP-17-37 and GLP-17-36 amide are equally potent 
at the GLP-1R.58 The GLP-1R is expressed in pancreatic islets, 
where GLP-1 functions as an incretin hormone. This allows for 
enhanced glucose-dependent insulin release post-prandially.59 
GLP-1 also inhibits glucagon secretion and delays gastric emp-
tying.60,61 The GLP-1R is also present in a number of CNS areas 
implicated in appetite control. These include the ARC and PVN 
in the hypothalamus and the AP in the brainstem.62,63 Neurons 
containing GLP-1 are located in the AP and NTS. Furthermore, 
there are projections to the dorsomedial hypothalamus.64
It is well established that administration of GLP-17-36 amide pe-
ripherally or centrally leads to reduced food intake in rodents, 
whereas co-administration of an antagonist of GLP-1 (exen-
din9-39) abolishes this effect.
65 In the same study, single admin-
istration of exendin9-39 doubled food intake in satiated rats in 
addition to potentiating the feeding response to NPY admin-
istration, suggesting that GLP-1 regulates appetite physiologi-
cally. 
A range of studies has demonstrated that peripheral admin-
istration of GLP-17-36 amide to humans leads to a dose-dependent 
reduction in appetite and ad libitum energy intake. A meta-
analysis of major studies by Verdich et al.66 revealed that intra-
venous infusion of GLP-17-36 amide reduces energy intake dose-
dependently in both lean and overweight subjects. The protocols 
in the individual studies within the meta-analysis varied con-
siderably, in addition to including a mixture of lean, overweight 
and obese subjects in the studies analysed. The duration of the 
infusions ranged between 0 and 240 minutes (spanning 60 
minutes in the majority of studies). Furthermore, the timing of 
the ad libitum buffet meal with regard to the infusion varied be-
tween studies. Finally, individual protocols varied such that the 
dose of infused GLP-17-36 amide in individual studies ranged be-
tween 0.375 pmol/kg/min and 1.5 pmol/kg/min. Amalgamating 
Table 2. Important Translational Human Studies Involving PYY3-36
Study Major findings
Batterham et al.37 In lean subjects, 36% reduction (compared with placebo) in ad libitum food intake at meal served 2 hours after 90 minute 
intravenous infusion of PYY3-36. 
In the same group, 33% reduction (compared with placebo) in 24 hour food intake following 90 minute intravenous infusion 
of PYY3-36.
Batterham et al.38 In overweight subjects, 30% reduction (compared with placebo) in ad libitum food intake at meal served 2 hours after 90 
minute intravenous infusion of PYY3-36.
Sloth et al.39 In lean and overweight subjects, 19% reduction (compared with placebo) in ad libitum food intake at meal served 2 hours 
after 90 minute intravenous infusion of PYY3-36.
Batterham et al.44 During placebo infusion, caloric intake correlated with functional MRI signal change in the hypothalamus. This correlation 
switched to the OFC when PYY3-36 was infused intravenously.
Gantz et al.48 Rapid absorption and significant nausea following prandial, intranasal administration of PYY3-36 to obese subjects over 12 
weeks.
Steinert et al.49 In lean subjects, effective absorption of oral PYY3-36 when delivered with sodium N-caprylate. 12% reduction (compared with 
placebo) in ad libitum food intake at meal served 15 minutes after oral PYY3-36.
PYY, peptide tyrosine tyrosine; MRI, magnetic resonance imaging; OFC, orbitofrontal cortex.
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the individual study data in the meta-analysis revealed that the 
mean infusion rate was 0.89 pmol/kg/min across all subjects. 
In lean subjects, infusion of GLP-17-36 amide led to a 13.2% reduc-
tion in energy intake at the ad libitum buffet meal compared 
with saline infusion. The reduction in ad libitum energy intake 
for overweight/obese subjects by GLP-17-36 amide was comparable 
(10.5%) with that of lean subjects.66 Data on nausea and other 
well-being scores were only included in 2 of the studies in the 
meta-analysis. Nausea was not encountered in either of these 
studies. In addition to the intravenous infusion studies described 
above, it was found that daily prandial subcutaneous injections 
of GLP-17-36 amide (76 nmol 4 times daily) to obese human sub-
jects over 5 days led to a 15% mean reduction in energy intake 
at each meal compared with placebo. Over 5 days, this trans-
lated to a mean weight loss of 0.55 kg.67 However, feelings of 
sickness were reported in 8 out of 19 subjects receiving prandial 
subcutaneous injections of GLP-17-36 amide, compared with 2 out 
of 7 subjects receiving placebo injections. 
The brainstem is thought to be an important site of action 
of peripheral GLP-1. In rodents, c-fos expression occurs in the 
brainstem only after the peripheral and not central injection of 
GLP-17-36 amide.
65 In contrast, both peripheral and central injection 
of GLP-17-36 amide induce c-fos in the PVN.
68 Furthermore, va-
gotomy or lesions of projections from the brainstem to the hy-
pothalamus reduce the appetite suppression mediated by periph-
eral GLP-17-36 amide.
69 In humans, a positron emission tomography 
(PET) study revealed that the post-prandial GLP-1 response is 
positively associated with changes in neuronal activity in the 
prefrontal cortex and hypothalamus.70 Therefore, as seems to be 
the case with PYY3-36, peripheral GLP-17-36 amide may either act 
via the vagus, with projections to the brainstem and then hy-
pothalamus, or alternatively may act directly on the brainstem 
(gaining access from the circulation at the AP) or hypothalamus 
(gaining access from the circulation at the median eminence). 
Furthermore, action on brain food reward regions (such as the 
pre-frontal cortex) is likely, either directly or through commu-
nication via homeostatic centres. A summary of the interactions 
of GLP-1 with the brainstem, hypothalamus and higher brain 
centres is shown in Fig. 2.
DEVELOPING GLP-1 BASED TREATMENTS FOR OBESITY
The fact that circulating GLP-1 is rapidly broken down by DPP-
IV has been a challenge to developing its use clinically. Exenatide 
(exendin-4) is a currently licensed DPP-IV resistant GLP-1R agonist 
that has enjoyed success in producing improved glycaemic control 
and promoting weight loss when administered subcutaneously to 
overweight patients with type 2 diabetes.71,72 Long acting analogues 
of GLP-1 such as liraglutide are also licensed for subcutaneous use 
in type 2 diabetes as adjunctive therapy, following favourable ef-
ficacy and safety data.73-76 The half-life of liraglutide is prolonged 
by albumin binding. The fact that exenatide and liraglutide 
produce an incretin effect is favourable in enhancing endog-
enous insulin secretion in response to a post-prandial glucose 
load. Furthermore, their effects of suppressing food intake and 
causing weight loss (through reduction in gastric emptying and 
central effects on the CNS as discussed above) makes this line of 
treatment particularly attractive in treating overweight patients 
with type 2 diabetes. However, one major limitation surrounds 
their well-recognised side effect of nausea. Although it occurs 
commonly, the incidence of nausea declines with duration of 
treatment.71,72
In order to avoid the need for injections, nonpeptidic GLP-
1R agonists in oral form have been developed and tested in 
rodents.77,78 Recently, delivery of oral GLP-17-36 with sodium N-
caprylate to healthy human subjects reduced energy intake by 
13.6% during a meal served 15 minutes later, with marked ef-
fects on glucose homeostasis.49 However, in this study, 24-hour 
energy intake was unaffected by GLP-17-36. 
In addition to GLP-1 receptor agonism, oral DPP-IV inhibitors 
such as sitagliptin and vildagliptin are also currently licensed as 
adjunctive therapy in type 2 diabetes. Although they confer the 
advantage of being available in oral form, unlike exenatide and 
liraglutide, they tend to be weight-neutral.79 This may well be 
due to the fact that DPP-IV has a role in activating other ano-
rectic hormones such as PYY3-36, hence DPP-IV inhibition may 
be counter-productive in this regard. Finally, although currently 
not licensed, GPR 119 agonists (i.e., GLP-1 secretagogues) are 
under development for use in type 2 diabetes.80
Outside of the context of type 2 diabetes, liraglutide has 
proven successful in causing significant weight loss when 
administered over 20 weeks to obese, non-diabetic patients.81 
Administration of liraglutide subcutaneously at a dose of 3 mg 
once daily led to a mean weight loss of 7.2 kg, compared with 
2.8 kg with placebo and 4.1 kg with orlistat 120 mg orally 3 
times daily. 76% of participants on liraglutide 3 mg once daily 
lost >5% body weight.81 Nausea and vomiting occurred more 
frequently in the liraglutide group than in the placebo group, 
but this rarely led to discontinuation of treatment. The results 
of this randomised, double-blind, placebo-controlled study hold 
promise for the licensing of GLP-1 analogues in obesity alone. 
A summary of important translational human studies inves-
tigating the role of GLP-1 in appetite control and as a potential 
treatment for obesity is shown in Table 3. 
DEVELOPING COMBINATION THERAPY BASED ON PYY 
AND GLP-1
Preliminary research has focused on deciphering the role and 
mode of action of individual gut hormones in appetite regula-
tion. However, more recently, there has been an interest in 
investigating how these satiety factors act in concert to regulate 
appetite. This is particularly relevant when considering that in 
the physiological fed state, a multitude of gut hormones are 
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released into the circulation. More effectively mimicking the 
physiological fed state using combination gut hormone ana-
logues may prove promising for the future treatment of obesity. 
In the case of PYY3-36 and GLP-17-36 amide, Neary et al.
82 showed 
that in 10 healthy, lean human subjects, co-administration of 
PYY3-36 and GLP-17-36 amide (each at 0.4 pmol/kg/min over 120 
minutes) produced a 27% reduction in ad libitum energy intake 
(compared with saline) during a buffet meal served 90 minutes 
into the infusion (the infusion was continued during the meal). 
Individually, single infusion of PYY3-36 and GLP-17-36 amide at the 
above doses did not produce a statistically significant reduction 
in energy intake compared with saline. Importantly, no nausea 
was experienced during any of the infusions, including the 
combined PYY3-36 and GLP-17-36 amide infusion. 
In the same paper,82 rodent studies were carried out and find-
ings strengthened those of the human study; combination of 
peripheral PYY3-36 and GLP-17-36 amide led to reduction in food 
intake that was greater than that observed when either hormone 
was infused individually at twice the dose. In the hypothalamic 
ARC, no changes were observed after low-dose PYY3-36 or GLP-
17-36 amide individually, but co-administration led to c-fos expres-
sion.
In a recent study of 12 healthy human subjects, co-admin-
istration of oral PYY3-36 and GLP-17-36 amide in conjunction with 
sodium N-caprylate lead to a 21.5% reduction in energy intake 
during a meal served 15 minutes later.49 Admittedly, 2 subjects 
experienced significant gastrointestinal side effects of nausea, 
abdominal discomfort and vomiting. Furthermore, 24-hour en-
ergy intake was no different compared with placebo.
CONCLUSION
The global obesity epidemic has escalated the need to dis-
cover new therapeutic strategies to counteract it. Lifestyle modi-
fication alone is largely ineffective in modern Western society, 
owing to the abundance of high-calorie food available at little 
cost, coupled with a generally sedentary lifestyle. The develop-
ment of bariatric surgical techniques over the past decade is a 
major breakthrough in treatment for the very obese, although 
the procedure is itself not without risk, cannot be tailored easily 
to individual need and does not address the needs of hundreds 
of millions of people who do not meet the requirements for the 
procedure, yet who remain at significant risk from the compli-
cations of being overweight or obese. 
The role of gut hormones in appetite control has been studied 
for over 30 years, with clear demonstration that they have a 
role in mediating post-prandial satiety. Despite this there has 
been no contribution from gut hormones to the pharmacologi-
cal market for obesity alone. Following gastric bypass surgery 
anorectic gut hormones, such as PYY and GLP-1, are elevated. 
They play a crucial role in the subsequent reduction in food 
intake. There has been renewed interest in the potential of these 
peptides to treat obesity. The concept of targeting a physiologi-
cal system and deceiving the brain into falsely believing that 
feeding has occurred would seem to hold more promise than 
targeting ubiquitous central neurotransmitter systems. The latter 
blunderbuss approach has led to the downfall of several previ-
ous pharmacological approaches to tackling obesity. Within 
the next few years, it is likely that we can look forward to the 
licensing of GLP-1 and PYY based treatments for obesity alone. 
Pharmacokinetic and pharmacodynamic hurdles will need to 
be overcome. Additionally, it is likely that in order to mimic a 
co-ordinated post-prandial satiety response, several anorectic 
gut hormone-based treatments may have to be administered in 
combination, perhaps along with antagonists of orexigenic hor-
monal signals. The overall goal will be to reproduce the physi-
ological consequences of a gastric bypass procedure solely by 
means of gut hormone based therapy, thereby effectively creat-
ing a ‘medical bypass.’ 
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Table 3. Important Translational Human Studies Involving GLP-1
Study Major findings
Verdich et al.66
(meta-analysis)
In lean subjects, 13.2% reduction (compared with placebo) in ad libitum food intake at meal served following intravenous 
infusion of GLP-17-36. Comparable 10.5% reduction in ad libitum food intake in overweight/obese subjects. Individual study 
protocols within the meta-analysis varied. 
Näslund et al.67 In obese subjects, 15% mean reduction in ad libitum energy intake at each meal (compared with placebo) following prandial, 
subcutaneous administration of GLP-17-36 over 5 days.
Pannacciulli et al.70 Post-prandial endogenous GLP-1 response correlated with positron emission tomography signal changes in the prefrontal 
cortex and hypothalamus.
Steinert et al.49 In lean subjects, effective absorption of oral GLP-17-36 when delivered with sodium N-caprylate. 13.6% reduction (compared 
with placebo) in ad libitum food intake at meal served 15 minutes after oral GLP-17-36.
Astrup et al.81 In obese, non-diabetic subjects, daily subcutaneous administration of liraglutide over 20 weeks led to a mean weight loss of 7.2 
kg (compared with 2.8 kg with placebo).
GLP-1, glucagon-like peptide 1.
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